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Abstract
Objective: Febrile seizures (FS) are the most common seizure type in young chil-
dren. Complex FS are a risk factor for mesial temporal lobe epilepsy (mTLE). To
identify new FS susceptibility genes we used a forward genetic strategy in mice
and subsequently analyzed candidate genes in humans. Methods: We mapped a
quantitative trait locus (QTL1) for hyperthermia-induced FS on mouse chromo-
some 1, containing the signal recognition particle 9 (Srp9) gene. Effects of differ-
ential Srp9 expression were assessed in vivo and in vitro. Hippocampal SRP9
expression and genetic association were analyzed in FS and mTLE patients.
Results: Srp9 was differentially expressed between parental strains C57BL/6J and
A/J. Chromosome substitution strain 1 (CSS1) mice exhibited lower FS suscepti-
bility and Srp9 expression than C57BL/6J mice. In vivo knockdown of brain Srp9
reduced FS susceptibility. Mice with reduced Srp9 expression and FS susceptibil-
ity, exhibited reduced hippocampal AMPA and NMDA currents. Downregulation
of neuronal Srp9 reduced surface expression of AMPA receptor subunit GluA1.
mTLE patients with antecedent FS had higher SRP9 expression than patients with-
out. SRP9 promoter SNP rs12403575(G/A) was genetically associated with FS and
mTLE. Interpretation: Our findings identify SRP9 as a novel FS susceptibility gene
and indicate that SRP9 conveys its effects through endoplasmic reticulum (ER)-
dependent synthesis and trafficking of membrane proteins, such as glutamate
receptors. Discovery of this new FS gene and mechanism may provide new leads
for early diagnosis and treatment of children with complex FS at risk for mTLE.
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Introduction
Febrile seizures (FS) occur in 2–5% of children between
the age of 6 months and 5 years.1 Of these affected chil-
dren, 30–40% develops complex FS.2 Prolonged or com-
plex FS last more than 15 min, are often recurrent, and
increase the risk of developing mesial temporal lobe epi-
lepsy (mTLE) later in life.2 Genetic factors appear to play
an important role in determining FS susceptibility. About
25% of children experiencing FS have a positive family
history and concordance for FS is about 40–60% in
monozygotic twins, but only 10–20% in dizygous twins.3,4
Several mutations have been identified in families with FS
or complex epilepsy syndromes with FS as a central fea-
ture, such as generalized epilepsy with FS (GEFS+) (for
review see5), but the genetic factors involved in common
forms of FS remain elusive. The aim of this study was to
identify new human FS susceptibility genes starting from
a phenotype-driven genetic strategy in mice.
Prolonged experimental FS can be elicited in rats by
inducing hyperthermia.6–8 To study the complex genetics
of FS we have adapted this model to mice, enabling
large-scale phenotypic screening of inbred strains for FS
susceptibility.9,10 Using this phenotypic screen on inbred
mice we established that FS susceptibility is distinct
from susceptibility for electrically- or chemically induced
seizures.9,10 Subsequently, we performed a phenotype-
driven screen for FS susceptibility employing the C57BL/
6J-Chr#A/NaJ chromosome substitution (CSS) panel11
and found that chromosome 1 (CSS1) has a strong con-
tribution to FS susceptibility.10 This panel has proven to
be a powerful tool in detecting quantitative trait loci for
complex traits in a relatively small number of F2
animals.11–13
Here, we mapped a quantitative trait locus (QTL) for
FS susceptibility on chromosome 1 and identified signal
recognition particle 9 (Srp9) as a FS susceptibility gene in
mice. Subsequent expression and association studies in FS
and mTLE patients provide compelling evidence for a role
of SRP9 and endoplasmic reticulum (ER)-dependent pro-
tein synthesis in human FS susceptibility. Interestingly,
similar local protein synthesis pathways were recently
implicated in disorders with high comorbidity with epi-
lepsy, such as Fragile X and autism.14,15
Materials and Methods
Animals
C57BL/6J and C57BL/6J-Chr 1A/NaJ (CSS1 and CSS2)
mice were obtained from The Jackson Laboratory (Bar
Harbor, ME). We generated a CSS1-F2 by intercrossing F1
hybrid animals from a (reciprocal) outcross between CSS1
and C57BL/6J (n = 129; 28 males, 31 females; 36 males and
34 females originating from CSS1 and C57BL/6J mothers,
respectively), which was pheno- and genotyped (10). Ani-
mals were kept in a controlled 12 h light–dark cycle (light
on 7.00 AM to 7.00 PM) with a room temperature of
22  1°C and a humidity of 60%. Food and water were
available ad libitum (2111 RMH-TM diet; Hope Farms,
Woerden, The Netherlands). All animals were housed in
Plexiglas cages (Macrolon type II, Techniplast, Milan, Italy)
with sawdust bedding and a paper tissue for nest building.
All experimental procedures were approved by the Animal
Ethics Committee of Utrecht University.
QTL analysis
FS susceptibility (phenotyping) was determined by induc-
ing hyperthermia in P14 pups by exposure to a warm-air
stream and measuring the latency to tonic-clonic seizures
(FSL).10 Genomic DNA isolated from spleen was geno-
typed using SNP and microsatellite markers (Table S1)
across chromosome 1, selected based on allelic differences
between C57BL/6J and A/J.12 After map construction,
QTL location and variance explained by each locus was
determined using MapQTL (version 4.0; Kyazma, Wagen-
ingen, the Netherlands).12,13
Microarray analysis, in situ hybridization
and immunohistochemistry
cDNA of P14 C57BL/6J (n = 3) and CSS1 (n = 3) brains
was analyzed by two-color oligonucleotide microarray
analysis.16,17 Radioactive in situ hybridization on coronal
(16 lm) cryosections from na€ıve P14 CSS1 (n = 5) and
C57BL/6J (n = 6) brains and Srp9 (anti)sense oligo’s
intracerebroventricularly (ICV) injected animals were
quantified with ImageJ (version 1.4.0) and expressed as
nCi/g.13 Controls with sense probes were devoid of signal.
In (anti)sense injected animals transcript levels were
quantified in the whole ipsilateral cortex in serial sections
320 lm before and 320 lm behind the injection site.
Penetration of probes after ICV injection was verified
using fluorescent Fluorescein (FIC) labeled oligos (Sigma-
Aldrich, Zwijndrecht, the Netherlands) (Fig. S1). (Anti)
sense probes were synthesized using mouse RNA as a
template (Primers, Table S2) (Sigma-Aldrich, The Nether-
lands). Immunocytochemistry18 on 7 lm paraffin sections
from P14 C57BL/6J and CSS1 mouse brains (n = 13)
using Srp9 antibody (dilution 1:500; Ptglab, Chicago, IL)
was quantified with ImageJ and expressed as percentage
of C57BL/6J staining. Protein expression was analyzed
blinded by two independent observers. Preabsorption of
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the antibody with a 10-fold excess of antigen (Ptglab,
USA) abolished all staining.
Functional interference studies in mice
Srp9 antisense (T*G*A*G*GCATCGTGGCT*T*C*A*G*
G; n = 12, *=phosphorothioate bond) or scrambled (Scr-1:
T*C*A*G*G*GTACGCGTCGT*A*G*C*G*T*, n = 12;
Scr-2:G*C*G*T*T*GCAAAGTCGGA*C*T*T*G*G, n =
10) oligonucleotides (18 nmol/L) (Sigma-Aldrich, The
Netherlands) were ICV injected (1.5 lL in 5 min) in anes-
thetized P14 C57BL/6J mice 20 h prior to hyperthermia
induction. Cycloheximide (20 mg/kg; Sigma, St. Louis,
MO), rapamycin (30 mg/kg; Santa Cruz Biotechnology,
Dallas, TX), or saline were injected intraperitoneally (IP) in
P14 C57BL/6J mice (n = 9 per group) 20 or 30 min before
hyperthermia induction, respectively. Latencies were deter-
mined blinded by two independent observers.
Electrophysiology
Voltage-clamp recordings were made from CA1 neurons
in hippocampal slices from P14 C57BL/6J (n = 6) or
CSS1 (n = 6) mice.19 One slice at a time was placed in a
recording chamber, continuously perfused with artificial
cerebrospinal fluid (ACSF) at 32°C, consisting of
120 mmol/L NaCl, 3.5 mmol/L KCl, 1.3 mmol/L MgCl2,
2.5 mmol/L CaCl2, 25 mmol/L NaHCO3, 1.25 mmol/L
KH2PO4, and 10 mmol/L D-glucose, pH 7.4. Bicucclline
methiodide (20 lmol/L, Enzo Life Sciences, Lorrach, Ger-
many) was added to the ACSF to prevent gamma-amino-
butyric acid-mediated inhibition. Whole cell recordings
were established with patch clamp electrodes (impedance
4–6 MO, 1.5 mm outer diameter, 0.86 mm inner diame-
ter, Harvard Apparatus LTD, Kent, U.K.) containing an
intracellular pipette solution of 120 mmol/L Cs methane-
sulfonate, 17.5 mmol/L CsCl, 10 mmol/L Hepes, 5 mmol/L
1,2-bis(o-aminophenoxy)ethane-N,N,N,N-tetraacitic acid,
2 mmol/L MgATP, 0.1 mmol/L NaGTP, and 10 mmol/L
QX-314, pH 7.4, adjusted with CsOH. The signals were
recorded using a patch clamp amplifier (Axopatch 200B;
Molecular Devices, Sunnyvale, CA). A concentric bipolar
electrode (outer pole 200 lm stainless steel, inner pole
25 lm Pt/Ir, FHC; Bowdoin, ME) was placed in the den-
dritic layer of the CA1 area. Input-output curves of the
excitatory postsynaptic currents (EPSCs) were evoked at a
holding potential of 70 mV to determine the half maxi-
mal stimulus intensity. The stimulus intensities ranged
from 7 to 600 lA. The half maximal stimulus intensity was
used to evoke EPSCs at holding potentials between 90
and +50 mV. AMPA current amplitudes were measured at
90 mV (C57BL/6J: 27 cells, CSS1: 28 cells) and NMDA
currents at 50 mV (C57BL/6J: 27 cells, CSS1: 24 cells)
(Fig. 3A).
Srp9-shRNA transfection
Functionally active Srp9-shRNAs (shRNA#1: GAGACCAG
CCTGTGTCCTA and shRNA#2: GAGTAGGAATGTCAG
GGTT) were constructed based on their potency (4 ON-
TARGETplus Srp9 siRNA, Dharmacon) to knockdown
Srp9 in transfected Neuro2A cells measured by Western
blot. Primary rat hippocampal cultures (E18)20,21 were
transfected at 14 days in vitro and co-transfected with a
GFP construct. Four days after transfection neurons were
incubated for 15 min with rabbit anti-GluA1 (1:20; Cal-
biochem, San Diego, CA) or Nr2a (1:20; Covance, Prince-
ton, NJ). After washing, neurons were fixed for 10 min in
4% PFA/4% sucrose and incubated with Alexa 568-conju-
gated goat anti-rabbit antibodies (1:400; Invitrogen, Carls-
bad, CA) in PBS 0.1% gelatin for 1 h at room
temperature. Coverslips were washed in PBS and
mounted in Vectashield (Vector Laboratories, Peterbor-
ough, U.K.). Confocal images were acquired using a
LSM510 confocal microscope (Zeiss) with a 409 oil
objective. Confocal images of transfected neurons were
obtained with sequential acquisition settings at the maxi-
mal resolution of the microscope (1024 9 1024 pixels).
Each image was a z-series of 6–10 images each averaged
two times. The resulting z-stack was “flattened” into a
single image using maximum projection. The confocal
settings were kept the same for all scans when fluores-
cence intensity was compared. Morphometric analysis and
quantification were performed using MetaMorph software
(Universal Imaging Corporation, Downingtown, CA).20,21
Human samples and DNA isolation
Hippocampal and neocortical tissues were obtained from
pharmaco-resistant mTLE patients with complex partial
seizures during surgical resective treatment.18 Hippocam-
pal tissue from autopsy controls (controls) was obtained
from the Netherlands Brain Bank. Patient selection (for
clinical data see Table S3), and collection and processing
of tissue for qPCR analysis was as described.17
DNA was isolated from neocortex of mTLE patients
(n = 368, 91 with FS), blood of patients with complex
and/or familial FS without mTLE (n = 145) and healthy
Dutch blood bank controls (n = 730). Hippocampal scle-
rosis (HS) was diagnosed on cresyl violet (Nissl)-stained
sections and classified according to the grading system of
Wyler by a neuropathologist.18 Where required informed
and written consent was obtained from the patients for all
procedures as approved by the Institutional Review Board.
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Quantitative PCR and Western blot
cDNA was synthesized from hippocampal RNA of con-
trols (n = 15), mTLE + HS (n = 21) and mTLE  HS
(n = 19). Within the mTLE + HS group we compared
patients with (+FS; n = 7) and without (FS; n = 14)
antecedent FS. Primers for SRP9, SRP68, and reference
genes PSMD2 and DDX48 were from Sigma Genosys
(Cambridge, U.K.). qPCR data were calculated as normal-
ized ratios and normalized to both reference genes.17
Western blotting with Srp9 antibody (1:2000; Ptglab,
USA) on hippocampal homogenates from controls
(n = 6), mTLE + HS (n = 12) and mTLE  HS (n = 11)
was quantified with ImageJ using b-actin as loading con-
trol. Western blot analysis showed a single 9 kDa band,
which was absent after preabsorption of the antibody with
a 10-fold excess of the antigen.18
Sequencing
Mouse Srp9 was sequenced as described.42 Primers
1–18 (Table S1) were chosen (Mus musculus Srp9 sequ-
ence in Ensembl (ENSMUSG00000026511, 183,755,349–
187,980,365 bp) to amplify promoter, 50 UTR, exons,
introns and 30UTR in C57BL/6J, A/J, and CSS1 mice
(n = 3). Human SRP9 exons, exon–intron boundaries
and promoter region (5 kb upstream) were sequenced
with nested PCR.22 Primers (Table S4) were chosen
using LIMSTILL (http://limstill.niob.knaw.nl/).22 All
sequenced SNPs with an allele frequency >0.05 were
selected for association analysis. SNP (rs12403575) geno-
typing (TaqMan SNP Genotyping Assays; Applied Bio-
systems, Foster City, CA) was performed on an ABI
PRISM 7900 Sequence Detection System (Applied Bio-
systems, Foster City, CA) and SDS 2.2.3 software for
allelic discrimination.13
Statistical analysis
Data were analyzed with SPSS (version 15.0) and
expressed as mean  SEM. One way analysis of variance
(ANOVA) was performed with a post hoc Bonferroni-
Dun test. Significance levels (a = 0.05) were corrected
with the Dunnett method to account for the multiple
(strain, expression, treatment or gene) comparison.
Equality of variances was tested with Levene’s test. P-val-
ues (two-tailed: all SNPs; one-tailed: rs12403575) of allele
frequencies were calculated by chi-square analysis with a
2 9 2 contingency table and corrected for multiple test-
ing. Distribution of genotypes was in Hardy–Weinberg
equilibrium. All other data were analyzed by an indepen-
dent t-test (a = 0.05).
Results
FS QTL mapping on mouse chromosome 1
To verify our observation that chromosome 1 has a
strong contribution to FS susceptibility,10 we determined
the latency of the C57BL/6J and CSS1 mice to develop
EEG-verified FS induced by hyperthermia.10 As expected,
the latency to FS (FSL) was higher in CSS1
(915.3  37.5 sec) than in C57BL/6J (631.9  26.9 sec)
(Fig. 1A). To map genes contributing to reduced FS sus-
ceptibility on mouse chromosome 1 we bred a CSS1-F2
generation. Phenotypic analysis of all individuals showed
that the majority of these genetically unique CSS1-F2
mice had a longer FSL than C57BL/6J mice (Fig. 1B).
QTL analysis revealed a highly significant peak
(LOD = 7.6) (Fig. 1C) (Table S1). The 1-LOD support
interval12 of this QTL1 was located between 183,756,349
and 187,980,365 bp that contains 29 protein coding
sequences (Table S5) and accounted for 23.9% of the var-
iance in the CSS1-F2 population (Table S1).
Identificaton of Srp9 as candidate FS
susceptibility gene
To identify candidate genes in QTL1, we compared mRNA
expression profiles of postnatal day (P14) C57BL/6J and
CSS1 mouse brains (DNA microarray data have been sub-
mitted to GEO [accession no GSE41320]). Of the 22 brain
expressed genes in the locus, Srp9 and three other genes
showed differential expression (Fig. 1D) between the
strains. Using the same mapping strategy in CSS2 mice,
we identified Srp14, the binding partner of Srp9 in the
SRP complex, as a strong candidate gene for FS suscepti-
bility in QTL2b (LOD = 6.2; 1-LOD interval 114,875,854–
133,817,501 bp) on chromosome 2 (Fig. S2). These obser-
vations prompted us to examine the differential expression
of Srp9 between CSS1 and C57BL/6J in more detail. In situ
hybridization (Fig. 1E) and immunocytochemistry
(Fig. 1F) confirmed that hippocampal Srp9 expression was
lower in CSS1 compared to C57BL/6J (mRNA:
35.6  6.3%, P = 0.001; protein: 25.6  5.0%, P =
0.003). Sequencing of Srp9 (184,053,433–184,063,607 bp)
in C57BL/6J, CSS1, and A/J mice identified one new SNP
in the 30UTR and 52 polymorphisms in intronic and pro-
moter regions (Fig. S3). Database analysis (WebQTL:
http://www.genenetwork.org/) revealed a strong cisQTL
for Srp9 mRNA regulation in the AXB eye tissue
(LOD = 12.1) and BXD brain (LOD = 11.7). Sequencing
2500 bp upstream showed a major 210 bp deletion in
A/J and CSS1, containing a SINE B2 element (Repeat-
Masker: http://www. repeatmasker.org/). The functional
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Figure 1. FS QTL mapping on chromosome 1. (A) The febrile seizure latency (FSL) of CSS1 (n = 9; 915.3  37.5 sec) is significantly longer than
of C57BL/6J (n = 9; 631.9  26.9 sec) mice (FStrain (1,14) = 11.355, P < 0.001) showing that CSS1 is less susceptible to FS. No sex differences
were found in either strain (Fgender (1,14) = 0.736, P = 0.406, interaction effect, Finteraction (1,14) = 0.104, P = 0.752). Strains did not differ in core
body-temperature increase during hyperthermia (data not shown; time F1,14 = 1478.191, P = 0.0001; time 9 strain F1,14 = 0.715, P = 0.511). (B)
Frequency histogram of FS latencies of CSS1-F2 progeny (n = 129) shows that, as expected, the majority of these genetically unique CSS1-F2
mice have a longer FSL than C57BL/6J (black bar is C57BL/6J average). (C) QTL1 (rs31997386, LOD = 7.6) located at 183,756,349–
187,980,365 bp (1-LOD support interval) accounts for 23.9% of the phenotypic variance. No sex or (grand) parent of origin differences in FSL
were observed for QTL mapping. (D) mRNA profiling in P14 C57BL/6J (n = 3) and CSS1 (n = 3) mouse brains revealed that of the 22 brain
expressed genes in the locus Srp9 and 3 other genes were differentially expressed (in bold) between strains (ratio CSS1/C57BL/6J, Bonferroni
corrected P-value for multiple testing, P < 0.05). (E) Autoradiograms after in situ hybridization (left panel) were quantified in the hippocampus
(right panel) showing that Srp9 mRNA was significantly (t9 = 5.090, P = 0.001) lower in CSS1 (n = 5; 78.7  7.0 nCi/g) than in C57BL/6J mice
(n = 6; 122.3  4.5 nCi/g). The reduction in Srp9 in total CSS1 brain was 23.1  6.4% (C57BL/6J: 90.2  3.9%, CSS1: 69.4  6.3%,
P = 0.001, data not shown). (F) Photomicrographs of immunocytochemistry (left panel) were quantified (right panel) showing that Srp9 protein
was significantly (t24 = 3.322, P = 0.003) lower in CSS1 (n = 13; 74.3  5.0%) than in C57BL/6J mice (n = 13; 100  5.8%). Srp9 was detected
in neurons and astrocytes. Error bars indicate SEM. *P < 0.05.
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consequences of this deletion and the polymorphisms are
subject of further study.
Effect of in vivo downregulation of Srp9 or
protein synthesis on FS susceptibility
To investigate a causal relationship between Srp9 expres-
sion levels and FS susceptibility, we microinjected Srp9
antisense (AS) oligonucleotides ICV in C57BL/6J pups
20 h prior to inducing hyperthermia. Srp9 knockdown
significantly prolonged FSL in C57BL/6J (869.0  52.3
sec) compared with littermates injected with two different
scrambled (Scr) oligonucleotides (P = 0.0001; Scr1:
630.2  45.4 sec; Scr2: 624.5  52.3 sec) (Fig. 2A) and
was accompanied by a downregulation (15%, P < 0.04)
of Srp9 transcript levels in the cortex (Fig. S4). Thus,
Srp9 downregulation in vivo decreased FS susceptibility
and induced the CSS1 FS phenotype in C57BL/6J. These
data show a causal relationship between Srp9 expression
and FS susceptibility. Because SRP9 is part of the SRP
complex, which couples cytoplasmic protein synthesis to
the membrane-bound protein translocation machinery of
the ER23–25 we independently assessed the importance of
protein synthesis in FS susceptibility. Protein synthesis
inhibitors were injected in C57BL/6J pups prior to hyper-
thermia induction to study the role of protein synthesis
in FS susceptibility. Cycloheximide, which inhibits trans-
lation initiation,26 significantly prolonged FSL (769.1 
41.1 sec) compared with saline injected littermates
(662.6  28.0 sec; P = 0.048) (Fig. 2B). Rapamycin,
which inhibits activation of eukaryotic translation initia-
tion factor 4B (eIF4B)27 through inhibition of mTOR
(mammalian target of rapamycin), also prolonged FSL
(708.1  35.9 sec) compared to saline injected littermates
(591.9  11.4 sec; P = 0.018) (Fig. 2B).
Effects of differential Srp9 expression on
AMPA and NMDA currents
The SRP complex plays a key role in the synthesis and
targeting of membrane proteins.23,24 Membrane receptors
which are pivotal to regulation of neuronal excitability
and susceptibility to seizures are glutamate receptors. As a
first step to analyze the relationship between Srp9 levels
and expression of functional glutamate receptors we com-
pared AMPA and NMDA currents in hippocampal slices
from P14 C57BL/6J and CSS1 mice, of which the latter
strain has reduced FS susceptibility and Srp9 expression.
Voltage-clamp recordings of CA1 neurons of CSS1 mice
revealed significantly smaller AMPA (20%, P = 0.041)
(Fig. 3B) and NMDA current amplitudes (30%,
P = 0.01) (Fig. 3C) than C57BL/6J mice.
Effects of downregulation of Srp9 on
surface expression of AMPA and NMDA
receptor subunits
To further investigate a role of Srp9 in regulating gluta-
mate receptor expression, we specifically downregulated
Srp9 expression by transfecting cultured hippocampal
neurons with Srp9-shRNAs and analyzing surface expres-
sion of AMPA and NMDA receptor subunits by immuno-
fluorescence (Fig. 4A). Srp9 knockdown neurons showed
a significant reduction (shRNA1 31%, P < 0.0001, and
Figure 2. Downregulation of Srp9 mRNA in C57BL/6J in vivo reduces FS susceptibility. (A) ICV injection of Srp9 antisense oligonucleotide (AS
Srp9) probe in C57BL/6J pups 20 h prior to hyperthermia significantly (F2,31=10.554, P = 0.0003) prolonged FSL (sec) in C57BL/6J (n = 12;
869.0  52.3 sec) mice compared to scrambled (Scr) probe injected littermate controls (Scr-1, n = 12; 630.2  45.4 sec, P = 0.001), and (Scr-2,
n = 10; 624.5  52.3 sec, P = 0.001). This in vivo treatment resulted in downregulation of Srp9 transcript levels (15%; P < 0.04) in the cortex
compared to controls. (B) IP injection of cycloheximide (CHX, n = 9; 769.1  41.1 sec) 20 min prior to hyperthermia delayed FSL (t16 = 2.141,
P = 0.048) compared to vehicle controls (n = 9; 662.6  28.0 sec). IP injection of rapamycin (RAP, n = 9; 708.1  35.9 sec) 30 min prior to
hyperthermia delayed FSL (t16 = 2.700, P = 0.018) compared to controls (n = 9; 591.9  11.4 sec). Error bar indicates SEM; *P < 0.05. ICV and
IP injections did not affect temperature curves during hyperthermia induction (data not shown).
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shRNA2 32%, P < 0.0001) in GluA1 surface expression
compared to vector controls (Fig. 4B), whereas Nr2a sur-
face expression was not significantly changed (shRNA1
8%, P = 0.130, shRNA2 7%, P = 0.126) (Fig. 4B).
SRP9 in patients with mTLE and FS
The identification of Srp9 as FS susceptibility gene in
mice, prompted us to investigated SRP9 in human FS
susceptibility. As a first step we measured SRP9 transcript
and protein levels in hippocampal tissue obtained during
surgery performed to treat patients with mTLE. We
compared mTLE patients with HS (mTLE + HS), known
to have a high incidence of antecedent FS (46% in this
study), with mTLE patients without HS (mTLE  HS),
and autopsy controls (Table S3). SRP9 mRNA expression
(Fig. 5A) was significantly higher (P = 0.0001) in
mTLE + HS (Rn = 209.0  24.4) than in mTLE-HS
patients (Rn = 100.0  8.2), and autopsy controls (Rn =
112.3  12.3). SRP9 protein (Fig. 5B) was also highest
(P = 0.005) in mTLE + HS patients (+HS: 223.2 
47.6%; HS: 100.0  11.6%; Control: 53.9  12.2%).
Within the mTLE + HS group we found significantly
higher SRP9 mRNA levels (+55.0%, P = 0.006) in patients
Figure 3. Reduced levels of Srp9 are associated with reduced glutamate receptor currents. Voltage-clamp recordings of CA1 neurons in
hippocampal slices of P14 mice. (A) AMPA current amplitudes were measured at 90 mV, NMDA current amplitudes at +50 mV. Quantification
of the amplitudes revealed smaller AMPA (B; t53 = 2.098, P = 0.041, C57BL/6J (n = 27); 1.37  0.1 CSS1 (n = 28); 1.10  0.1) and NMDA
currents (C; t49 = 2.687, P = 0.01, C57BL/6J (n = 27); 0.26  0.02 CSS1 (n = 24); 0.18  0.01) in CSS1 compared to C57BL/6J mice.
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Figure 4. Downregulation of Srp9 in neuronal cultures reduces GluA1 surface expression. (A) Knockdown of Srp9 reduced neuronal GluA1
surface expression (red) in GFP + shRNA transfected neurons (green). Representative images of hippocampal neurons stained for endogenous
surface GluA1. Hippocampal neurons at DIV14 were cotransfected with GFP (green) and pSuper control vector (CTRL) or Srp9-shRNA#1 or Srp9-
shRNA#2. At DIV18, neurons were stained live with anti-GLUA1 antibodies (red). Srp9-shRNA#1 knockdown neurons showed a significant
reduction (31%; P < 0.005) in surface labeling for GluA1 compared to controls. Bar is 20 lm. (B) Histograms show quantification of
fluorescence intensity of surface GluA1 (black bars) and Nr2a (white bars) staining relative to the intensity of GFP transfected control neurons at
basal levels (Crtl = control, sh1 = shRNA#1, sh2 = shRNA#2). GluA1 (F2,86 = 15.581. P = 0.0001); Ctrl = 100  5.6 shRNA#1 = 68.9  4.3,
shRNA#2 = 68  5.4, and Nr2a, (F(2,97) = 1.388, P = 0.254) Crtl = 100  3.0, shRNA#1 = 92.3  4.1, shRNA#2 = 93.2  3.5. n = 20 cells for
each group, 4–5 measurements per cell. White bar is 20 lm. Error bars indicate SEM. *P < 0.005.
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with antecedent FS (n = 7, Rn = 297.0  44.0) than in
patients without (n = 14, Rn = 164.5  21.5). Expression
of SRP68, a SRP protein not directly interacting with
SRP9, did not differ between the three groups, indicating
that not all SRP proteins are differentially expressed.
These data suggest that also in humans increased SRP9
expression may be linked to FS susceptibility.
In search for a genetic variant associated with FS and
mTLE, we subsequently sequenced all four exons of the
human SRP9 gene and its promoter region (5 kb) in a
Dutch mTLE patient cohort (n = 368) including 91
patients with antecedent FS, and ethnically matched healthy
controls (n = 169) (Fig. 5C). We did not find significant
differences in frequency of sporadic mutations between
groups nor did we find variants in coding sequences that
are predicted to affect protein function. Analysis of the fre-
quency of the 5 most common SNPs revealed a significant
association of a single SNP in the promoter region
Figure 5. SRP9 expression and sequencing in patients with mTLE and/or FS. (A) SRP9 mRNA levels (normalized qPCR data: Rn) in hippocampal
homogenates of autopsy controls (Control; n = 15; Rn = 112.3  12.3) and mTLE patients without (non-HS; n = 19; Rn = 100.0  8.2) and with
hippocampal sclerosis (HS; n = 21; Rn = 209.0  24.4). (F2,52 = 12.023, P = 0.0001; non-HS vs. HS: P = 0.008; Control vs. HS: P = 0.001;
Control vs. non-HS: P = 1.000). SRP68 mRNA levels did not differ between groups (Control Rn = 107.8  17.6; non-HS Rn = 100.0  8.1; HS
Rn = 115.1  19.3; F2,36 = 0.203, P = 0.817. (B) SRP9 protein (insert shows Western blot with loading control b-actin) in hippocampal
homogenates of Controls (n = 6; 53.9  12.2), non-HS (n = 12; Rn = 100.0  11.6), and HS (n = 11; Rn = 223.2  47.6) patients.
(F2,26 = 6.685, P = 0.005; non-HS vs. HS: P = 0.023; Controls vs. HS: P = 0.009; Controls vs. non-HS: P = 1.000). Error bar indicates SEM.
*Significantly different after multiple testing correction P < 0.01. (C) Sequencing of SRP9 exons, intron/exon boundaries and promoter region
(5 kb) in healthy controls (n = 169), mTLE patients (n = 368) and mTLE patients with FS (n = 91) revealed a significant (P < 0.01 bold) difference
in allele frequencies of one common promoter SNP (rs12403575 G/A) in mTLE patients. P-value corrected for multiple SNP testing P < 0.01. All
SNPs in the sequenced region with an allele frequency >0.05 were selected for the assocation study. In the HS group 46% had antecedent FS, in
the non-HS group only 6%. (D) Further single SNP analysis using a larger control cohort (n = 730) identified a significant association between
rs12403575 and mTLE (n = 368, P = 0.01, odds ratio (OR) = 1.238). This association was replicated in patients with FS without mTLE (n = 236,
P = 0.038, OR = 1.212). (E) Patients with AA genotype had a significantly (F2,33 = 4.142, P = 0.023) higher hippocampal SRP9 expression
(Rn = 169.7  22.9) than patients with AG genotype (Rn = 105.9  13.1, P = 0.044), and GG genotype (Rn = 103.1  19.6, P = 0.058). Data
are expressed as means  SEM. *Significantly different P < 0.05.
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(rs12403575 G/A) (Fig. 5C) with mTLE. Taqman analysis
of this SNP in the mTLE cohort and a larger control sample
(n = 730) revealed a significant association with mTLE
(P = 0.01, odds-ratio [OR] = 1.238) (Fig. 5D), and
mTLE + FS (P = 0.045, OR = 1.321). The association with
FS was confirmed in a cohort of FS patients (P = 0.038,
OR = 1.212) (Fig. 5D). By correlating SNP genotype and
hippocampal SRP9 expression levels in individual mTLE
patients, we found significantly higher SRP9 expression
(P = 0.023) in patients with AA (169.7  22.9) as com-
pared to AG (105.9  13.1), and GG genotypes
(103.1  19.6) (Fig. 5E), indicating that this SNP may
contribute to regulation of SRP9 expression.
Discussion
Common forms of FS are considered to be genetically
complex disorders, believed to be influenced by variations
in several susceptibility genes and the environment. From
association studies so far, no convincing FS susceptibility
genes have emerged.5 We, therefore, applied a new
approach to unravel the genetic complexity of FS by
employing a phenotype-driven genetic strategy in a con-
trolled laboratory setting inducing experimental complex
FS by hyperthermia in mice.10 Here we mapped a FS
QTL on chromosome 1 and identified Srp9 as FS suscep-
tibility gene by establishing a causal relationship between
FS and Srp9 expression levels in mice. On the basis of
this established causality in mouse, we probed the
hypothesis that SRP9 is also involved in human FS sus-
ceptibility. Studies in hippocampal tissue from mTLE
patients operated to treat seizures, showed that SRP9 lev-
els were significantly higher in mTLE patients with ante-
cedent FS than in mTLE patients without FS. Prompted
by these human data we performed an association study
and found a significant association of promotor SNP
(rs12403575) with FS and mTLE. This association could
be confirmed in FS patients, providing compelling evi-
dence for a role of SRP9 in human FS.
SRP9 is a subunit of SRP, a ubiquitous, highly conserved
cytoplasmic ribonucleoprotein complex that plays a key
role in targeting nascent membrane proteins to the rough
ER membrane.23 SRP contains two functional domains.
The S-domain (SRP19, 54, 68, and 72) is primarily involved
in recognition of the signal sequence of nascent peptide
chains, and the ALU domain (7SL RNA and the SRP9/
SRP14 heterodimer) is thought to be responsible for elon-
gation arrest facilitating targeting of nascent chains to the
ER.24,25 Interestingly, using the same forward genetic map-
ping strategy, we identified Srp14, the binding partner of
Srp9, as a strong candidate gene in a FS susceptibility QTL
on chromosome 2. Thus, our data indicate a role of the
ALU domain of the SRP complex in FS.
To independently assess the importance of protein syn-
thesis in FS susceptibility, we injected protein synthesis
inhibitors in C57BL/6J pups prior to hyperthermia induc-
tion. Cycloheximide, which inhibits translation initia-
tion,26 and Rapamycin, which inhibits activation of
eIF4B27 through inhibition of mTOR, both prolonged
FSL. mTOR signaling has been implicated in the patho-
genesis of tuberous sclerosis complex, a syndrome with a
prominent epilepsy phenotype.28 The rapid effect of pro-
tein synthesis inhibitors (20–30 min) indicates involve-
ment of local protein synthesis, possibly in dendrites and/
or synapses,29 where it is thought to play a key role in
regulating neuronal plasticity.29,30 Further studies will be
required to investigate whether Srp9 affects seizure sus-
ceptibility via local synaptic protein synthesis. Interest-
ingly, very recent studies on disorders with strong
comorbidity with epilepsy such as Fragile X syndrome
and Autism, identified genes in similar pathways.14,15
Fragile X syndrome is caused by a loss of function of the
RNA-binding protein Fragile X mental retardation pro-
tein, affecting local protein synthesis and synaptic plastic-
ity.15 Recent studies on autism spectrum disorder have
identified genes and pathways involved in synaptic matu-
ration and function, often as a result of alterations in
local protein synthesis.14
What could be the mechanism by which SRP9 conveys
its effect on FS susceptibility? SRP lacking SRP9/14 lacks
elongation arrest activity, but is still translocation compe-
tent, albeit, at lower efficiency.31 Presumably loss of SRP9
from the complex leads to loss of elongation arrest and
decreased translocation efficiency due to the strict time
dependence of the functional interaction between poly-
some and microsomal membrane.32,33 Therefore, reduced
SRP9 levels could affect the amount and/or composition
of proteins targeted to the ER, thus affecting secretion,
plasticity, and cell growth.32,33 Not only fever and FS but
also other risk factors for mTLE, such as viral infection,
stroke or head traumas are known to disrupt ER func-
tion.34,35 Not only ER function but also post-ER traffick-
ing maybe affected by SRP9 levels. For example, in HeLa
cells downregulation of several SRP proteins resulted in
reduced expression of membrane proteins, possibly
involving trafficking.32,33 Interestingly, receptor trafficking
defects have previously been implicated in FS.36,37 Thus,
it is plausible that variations in SRP9 levels observed in
this study, affect the expression of membrane proteins,
such as glutamate receptors at the postsynaptic mem-
brane, resulting in altered susceptibility to FS.
To test this hypothesis, we compared AMPA and NMDA
currents in hippocampal slices from P14 C57BL/6J and
CSS1 mice, of which the latter strain has reduced FS
susceptibility and Srp9 expression. In line with our hypoth-
esis voltage-clamp recordings of CA1 neurons of CSS1
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mice revealed significantly smaller AMPA and NMDA
current amplitudes than C57BL/6J mice. To confirm a role
of Srp9 in the regulation of glutamate receptor expression
we downregulated Srp9 expression in hippocampal
neurons. Knockdown of Srp9 expression resulted in
reduced GluA1 surface expression compared to vector
controls, whereas Nr2a surface expression was unaffected.
These results are in line with previous studies in hippo-
campal cultures showing that membrane NMDA receptors
are more stable, have a lower turnover, and are less
susceptible to regulation than AMPA receptors.38,39 Studies
on effects of Srp9 downregulation on other membrane
receptors are in progress. In all, our results indicate
that reduced Srp9 expression is associated with reduced
glutamate receptor expression and function. Glutamate
receptors are crucial regulators of neuronal excitability
and synaptic strength, and play a key role in synaptic
plasticity.40
In summary, our SRP9 data show an association with
both FS and mTLE. Complex FS are seen in 30–50% of
patients with mTLE.2 Due to the genetic complexity of
TLE it has been difficult to identify susceptibility genes.41
This study provides evidence for a role of Srp9 in both
FS and mTLE, thus indicating that they share at least
some common genetic predisposition. This is in line with
results from a recent study in mTLE patients with HS
showing a genome-wide significant association for mTLE
with HS with FS for an intron SNP in SCN1A; no associ-
ation was found for this SNP and FS alone in patients
who did not go on to develop epilepsy.42 Srp9 appears to
convey its effect on FS susceptibility through ER-depen-
dent protein synthesis and trafficking, resulting in altered
expression of cell membrane proteins, such as glutamate
receptor subunits. Identification of this new FS suscepti-
bility gene and mechanism may contribute to the devel-
opment of new tools for treatment of children with
complex FS and at risk for mTLE.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Penetration of fluorescent (FIC) oligo’s in the
P14 C57BL/6J brain 3 h after ICV injection. (A) Only faint
staining around the contralateral lateral ventricle. (B) Strong
labeling around the ipsilateral lateral ventricle (1) which
gradually decreases further into the cortex (2) and hippo-
campus (3). (C) Faint staining of the contralateral hippo-
campus. (D) Staining in the ipsilateral hippocampus
gradually decreases away from the ventricle (top to bottom).
Note the principle neuron layers (CA1 (4), CA3 (5) and
dentate granule cell layer (6)). (E) Detail of FIC labeling in
cortical cells. (F) DAPI nuclear staining. (G) Merge panels F
and G confirming cellular penetration of oligo’s.
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Figure S2. Mapping of two FS susceptibility QTLs on chro-
mosome 2. QTL analysis was performed on n = 144 CSS2-
F2 mice. QTL2a (D2Mit156; LOD = 3.6; 1-LOD support
interval 52,581,428–66,278,629 bp). QTL2b (D2Mit277;
LOD = 6.2; 1-LOD support interval 114,875,854–
133,817,501 bp) contains the Srp14 gene.
Figure S3. Srp9 sequence differences between C57BL/6J and
A/J/CSS1. Srp9 was sequenced (n = 3) in the CSS1, A/J and
C57BL/6J mice. A/J/CSS1 and C57BL/6J differences are in
red between parentheses. The exon region is in bold. Newly
identified polymorphisms are in bold and underlined
(known polymorphisms http://www.ensembl.org). The
210 bp underlined promoter region in bold was not present
in the A/J/CSS1.
Figure S4. Downregulation of cortical Srp9 mRNA 20 h
after ICV injection of Srp9 (anti)sense in P14 C57BL/6J
mice. Radioactive in situ hybridization was quantified in the
whole ipsilateral cortex in 16 µm serial cryosections
320 µm before, at (0 µm), and 320 µm after the injection
site using ImageJ. Black bars: scrambled Srp9 (Control;
n = 5); white bars: antisense Srp9 (Srp9; n = 7). The overall
downregulation in the ipsilateral cortex between 320 µm
and 320 µm (comparing sense and antisense injected ani-
mals) was 15% (P < 0.04).
Table S1. Cosegregation analysis in the CSS1-F2 progeny.
Table S2. Primers used for sequencing mouse Srp9, mouse
in situ hybridization and human quantitative PCR.
Table S3. Clinical data of patients used for expression stud-
ies.
Table S4. Primers used for nesting PCR to sequence SRP9
and the taqman assay for SNP rs12403575.
Table S5. Protein-coding genes in 1-LOD support interval
of QTL1.
250 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Srp9 is a Febrile Seizure Susceptibility Gene E. V. S. Hessel et al.
